STAB - Statera advances research based on STAT-200 platform aimed at inflammatory diseases

Statera Biopharma (STAB -11.4%) said it advanced research activities that builds upon its STAT-200 platform to improve drug characteristics and clinical benefit beyond opioid receptors. The research is based on the discovery that STAT-200, which was originally designed to antagonize opioid receptors, modulates multiple signaling pathways through receptors known as Toll-Like Receptors (TLRs). These receptors act as controllers of inflammation. STAB’s discovery platform identifies new compositions that build upon STAT-200 by modulating multiple cellular targets, versus one, to restore cellular homeostasis. These findings have led to the selection of promising new compositions with the potential to treat a range of inflammatory-related diseases. The company said the platform rapidly screened billions of potential compositions, resulting in hundreds of promising targets. Three of these are currently being synthesized for biologic validation. Statera collaborated with MolSoft to conduct the computational discovery through its proprietary Rapid Isostere Discovery Engine technology.

For further details see:

Statera advances research based on STAT-200 platform aimed at inflammatory diseases